- Home
- ADPT vs NAC Comparison
ADPT vs NAC Comparison
Compare ADPT & NAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- NAC
- Stock Information
- Founded
- ADPT 2009
- NAC 1998
- Country
- ADPT United States
- NAC France
- Employees
- ADPT N/A
- NAC N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- NAC Investment Managers
- Sector
- ADPT Health Care
- NAC Finance
- Exchange
- ADPT Nasdaq
- NAC Nasdaq
- Market Cap
- ADPT 1.8B
- NAC 1.6B
- IPO Year
- ADPT 2019
- NAC N/A
- Fundamental
- Price
- ADPT $12.61
- NAC $11.55
- Analyst Decision
- ADPT Strong Buy
- NAC
- Analyst Count
- ADPT 8
- NAC 0
- Target Price
- ADPT $12.38
- NAC N/A
- AVG Volume (30 Days)
- ADPT 1.8M
- NAC 307.3K
- Earning Date
- ADPT 11-06-2025
- NAC 01-01-0001
- Dividend Yield
- ADPT N/A
- NAC 4.33%
- EPS Growth
- ADPT N/A
- NAC N/A
- EPS
- ADPT N/A
- NAC N/A
- Revenue
- ADPT $205,216,000.00
- NAC N/A
- Revenue This Year
- ADPT $32.76
- NAC N/A
- Revenue Next Year
- ADPT $15.81
- NAC N/A
- P/E Ratio
- ADPT N/A
- NAC N/A
- Revenue Growth
- ADPT 21.60
- NAC N/A
- 52 Week Low
- ADPT $3.98
- NAC $9.32
- 52 Week High
- ADPT $13.68
- NAC $11.21
- Technical
- Relative Strength Index (RSI)
- ADPT 51.14
- NAC 73.15
- Support Level
- ADPT $12.34
- NAC $11.13
- Resistance Level
- ADPT $13.68
- NAC $11.64
- Average True Range (ATR)
- ADPT 0.56
- NAC 0.07
- MACD
- ADPT -0.08
- NAC 0.04
- Stochastic Oscillator
- ADPT 20.15
- NAC 82.35
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.